WCLC 2025 - Posters & ePosters-EP.12.13 Gradually or Locally Progressed NSCLC Patients Benefit From Aumolertinib in Post-1L Dose-Escalation Treatment

EP.12.13 Gradually or Locally Progressed NSCLC Patients Benefit From Aumolertinib in Post-1L Dose-Escalation Treatment

Pdf Summary

This study evaluated the efficacy and safety of high-dose aumolertinib as a post-first-line (post-1L) dose escalation treatment for patients with advanced non-small cell lung cancer (NSCLC) showing gradual or localized progression after initial therapy. Aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI), selectively targets classical EGFR mutations and EGFR T790M mutations, though resistance inevitably develops. Continuous EGFR-TKI treatment is typically advised for patients with localized progression.<br /><br />Forty-eight patients with histologically confirmed metastatic NSCLC who had previously been treated with standard-dose aumolertinib (110 mg daily) were enrolled; 11 received 165 mg and 37 received 220 mg daily depending on brain metastasis status. The median patient age was 63 years; 42% were male, and 22% were current or former smokers.<br /><br />At data cutoff, 30 patients experienced disease progression after dose escalation. The median progression-free survival after dose escalation (PFS2) was 13.2 months (95% CI 8.1–21.3), with an objective response rate (ORR) of 70.8% and disease control rate (DCR) of 100%. The overall median progression-free survival from first-line treatment initiation (PFS1) was 32.4 months (95% CI 26.4–36.5). Median overall survival (OS) had not yet been reached. Adverse events were mild, with no grade 3 or higher toxicities; common side effects included rash and diarrhea.<br /><br />The findings suggest that high-dose aumolertinib is a viable therapeutic option for NSCLC patients developing resistance during first-line EGFR-TKI therapy, providing promising efficacy and an acceptable safety profile. The study recommends future large-scale, multi-center clinical trials to optimize dosing strategies and refine patient selection to maximize clinical benefit.

Asset Subtitle

Jun Li

Meta Tag

Speaker Jun Li

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

aumolertinib

non-small cell lung cancer

NSCLC

EGFR-tyrosine kinase inhibitor

EGFR T790M mutation

dose escalation

progression-free survival

objective response rate

disease control rate

adverse events